Opinion|Videos|June 5, 2024
Advancing Pulmonary Arterial Hypertension Care: Overcoming Challenges in Special Populations and Exploring Innovative Approaches
Author(s)Ioana Preston, MD
Ioana Preston, MD, highlights treatment considerations for managing PAH in specific patient populations and discusses the unmet needs that can be addressed by novel therapeutic approaches or improved treatment strategies.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- What are the challenges associated with managing pulmonary arterial hypertension (PAH) in specific patient populations, such as those with comorbidities?
- How can the unmet needs in PAH be addressed through the development of novel therapeutic approaches or improved disease management strategies?
Advertisement
Related to this article
Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content spanning from glaucoma to dry eye.
A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Bumetanide nasal spray is bioequivalent to oral bumetanide in 68 healthy adults; Esperion is targeting heart failure care before a 2027 CMS payment model.
The trade group says CMS lacks authority to impose GLOBE, which is set to begin January 1.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
3
FDA Approves First Symptomatic Dermographism Treatment
4
Sacral Neuromodulation Still Seen as OAB Gold Standard in Review
5